PECAM is an effective and safe anthracycline-containing third-line regimen for patients with relapsed or refractory non-Hodgkin lymphoma

Fumi NakamuraDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan

Honoka AraiDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan

Katsuya TokitaDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan

Shiho FuruichiDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan

Fusako Sugita-NagasawaDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan

Wataru TakahashiDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan

Tomoyuki HandaDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan

Hisako IsoDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan

Jiro TadokoroDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan

Shigeharu TsurumiDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan

Yuko NakamuraDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan

Yuka NakamuraDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan

Ko SasakiDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan

Sachiko SeoDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan

Motoshi IchikawaDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan

Kinuko MitaniDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, JapanCorrespondence[email protected]

Your download is now in progress and you may close this window